Contribution Agreement from Treasury Board via National Research Council Canada
In Particle Physics, TRIUMF will support the Canadian community in alignment with the subatomic-physics Long Range Plan. In particular, TRIUMF will support extracting and analyzing the physics from the T2K experiment in Japan, the ATLAS and ALPHA experiments at CERN, and the PIENU experiment at TRIUMF.
In Nuclear Physics, TRIUMF will support the Canadian and international community in alignment with the subatomic-physics Long Range Plan. In particular, TRIUMF will develop rare-isotope beams from actinide targets required for the ISAC experimental program. TRIUMF will complete the installation and commissioning of EMMA and IRIS by 2013.
In Nuclear Medicine, TRIUMF will support the development of Canadian leadership in nuclear medicine and molecular imaging. In particular, TRIUMF will complete development of the localized Good Manufacturing Practice laboratory. TRIUMF will produce medical isotopes for the Pacific Parkinson's Program and will develop and deliver medical isotopes for research with the British Columbia Cancer Agency.
In Materials and Molecular Science, TRIUMF will support the scientific community and, in particular, will complete the construction and commissioning of the M-9A and M-20 muon beam lines in 2012.
For the Advanced Rare IsotopE Laboratory supported by multiple agencies and partners, TRIUMF will meet the following milestones:
- Fabrication & assembly of the first Injector Cryomodule & a 30 kW beam test will be completed by March 31, 2012.
- Civil construction of the ARIEL facility will be nominally complete by March 31, 2013.
- Installed in the Proton Hall, the e-linac will deliver low-current beams at 25 MeV by March 31, 2014.
- Electron beams at 25 MeV, 100 kW will be delivered by March 31, 2015.
TRIUMF : Canada's National Laboratory for Particle and Nuclear Physics
